World's Best Scientists 2026 revealed!

D-Index & Metrics

Biology and Biochemistry

D-Index
63
Citations
12787
World Ranking
10323
National Ranking
282

Helen Rizos publication distribution in Biology and Biochemistry in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Biology and Biochemistry in 2026. The highlighted bar marks where Helen Rizos sits on this spectrum.

47–56 publications: 8 scientists 57–66 publications: 35 scientists 67–76 publications: 106 scientists 77–86 publications: 231 scientists 87–96 publications: 414 scientists 97–106 publications: 546 scientists 107–116 publications: 704 scientists 117–126 publications: 849 scientists 127–136 publications: 980 scientists 137–146 publications: 942 scientists 147–156 publications: 969 scientists 157–166 publications: 950 scientists 167–176 publications: 951 scientists 177–186 publications: 915 scientists 187–196 publications: 787 scientists 197–206 publications: 841 scientists 207–216 publications: 735 scientists 217–226 publications: 709 scientists 227–236 publications: 651 scientists 237–246 publications: 605 scientists 247–256 publications: 510 scientists 257–266 publications: 524 scientists 267–276 publications: 434 scientists 277–286 publications: 418 scientists 287–296 publications: 350 scientists 297–306 publications: 363 scientists 307–316 publications: 315 scientists 317–326 publications: 296 scientists 327–336 publications: 261 scientists 337–346 publications: 240 scientists 347–356 publications: 219 scientists 357–366 publications: 197 scientists 367–376 publications: 154 scientists 377–386 publications: 161 scientists 387–396 publications: 155 scientists 397–406 publications: 145 scientists 407–416 publications: 124 scientists 417–426 publications: 112 scientists 427–436 publications: 132 scientists 437–446 publications: 116 scientists 447–456 publications: 99 scientists 457–466 publications: 81 scientists 467–476 publications: 91 scientists 477–486 publications: 80 scientists 487–496 publications: 80 scientists 497–506 publications: 60 scientists 507–516 publications: 36 scientists 517–526 publications: 46 scientists 527–536 publications: 54 scientists 537–546 publications: 44 scientists 547–556 publications: 43 scientists 557–566 publications: 43 scientists 567–576 publications: 42 scientists 577–586 publications: 25 scientists 587–596 publications: 34 scientists 597–606 publications: 23 scientists 607–616 publications: 33 scientists 617–626 publications: 31 scientists 627–636 publications: 27 scientists 637–646 publications: 25 scientists 647–656 publications: 28 scientists 657–666 publications: 34 scientists 667–676 publications: 18 scientists 677–686 publications: 16 scientists 687–696 publications: 10 scientists 697–706 publications: 12 scientists 707–716 publications: 21 scientists 717–726 publications: 12 scientists 727–736 publications: 12 scientists 737–746 publications: 10 scientists 747–756 publications: 7 scientists 757–766 publications: 13 scientists 767–776 publications: 15 scientists 777–786 publications: 13 scientists 787–796 publications: 9 scientists 797–806 publications: 9 scientists 807–816 publications: 7 scientists 817–826 publications: 4 scientists 827–836 publications: 9 scientists 837–846 publications: 7 scientists 847–856 publications: 3 scientists 857–866 publications: 5 scientists 867–876 publications: 5 scientists 877–886 publications: 11 scientists 887–896 publications: 3 scientists 897–906 publications: 4 scientists 907–916 publications: 7 scientists 917–926 publications: 5 scientists 927–936 publications: 6 scientists 937–946 publications: 6 scientists 947–956 publications: 3 scientists 957–966 publications: 7 scientists 967–976 publications: 2 scientists 977–986 publications: 2 scientists 987–996 publications: 1 scientists 997–1,006 publications: 5 scientists 1,007–1,016 publications: 2 scientists 1,017–1,026 publications: 2 scientists 1,027 publications: 1 scientists 1,028+ publications: 100 scientists
47 publications 1,028+

This scientist: 291 publications — 77th percentile

77% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,028 publications or more.

Helen Rizos D-index placement in Biology and Biochemistry in 2026

The chart shows the D-index (discipline H-index) distribution of Biology and Biochemistry scientists ranked by Research.com in 2026. The highlighted bar marks where Helen Rizos sits on this spectrum.

40–41 D-Index: 80 scientists 42–43 D-Index: 183 scientists 44–45 D-Index: 317 scientists 46–47 D-Index: 504 scientists 48–49 D-Index: 718 scientists 50–51 D-Index: 900 scientists 52–53 D-Index: 1,026 scientists 54–55 D-Index: 1,150 scientists 56–57 D-Index: 1,236 scientists 58–59 D-Index: 1,253 scientists 60–61 D-Index: 1,163 scientists 62–63 D-Index: 1,131 scientists 64–65 D-Index: 1,032 scientists 66–67 D-Index: 897 scientists 68–69 D-Index: 814 scientists 70–71 D-Index: 715 scientists 72–73 D-Index: 709 scientists 74–75 D-Index: 596 scientists 76–77 D-Index: 512 scientists 78–79 D-Index: 473 scientists 80–81 D-Index: 412 scientists 82–83 D-Index: 373 scientists 84–85 D-Index: 358 scientists 86–87 D-Index: 285 scientists 88–89 D-Index: 273 scientists 90–91 D-Index: 227 scientists 92–93 D-Index: 208 scientists 94–95 D-Index: 193 scientists 96–97 D-Index: 153 scientists 98–99 D-Index: 157 scientists 100–101 D-Index: 148 scientists 102–103 D-Index: 120 scientists 104–105 D-Index: 113 scientists 106–107 D-Index: 100 scientists 108–109 D-Index: 86 scientists 110–111 D-Index: 67 scientists 112–113 D-Index: 72 scientists 114–115 D-Index: 73 scientists 116–117 D-Index: 64 scientists 118–119 D-Index: 53 scientists 120–121 D-Index: 60 scientists 122–123 D-Index: 54 scientists 124–125 D-Index: 43 scientists 126–127 D-Index: 38 scientists 128–129 D-Index: 49 scientists 130–131 D-Index: 26 scientists 132–133 D-Index: 18 scientists 134–135 D-Index: 23 scientists 136–137 D-Index: 32 scientists 138–139 D-Index: 32 scientists 140–141 D-Index: 27 scientists 142–143 D-Index: 19 scientists 144–145 D-Index: 22 scientists 146–147 D-Index: 12 scientists 148–149 D-Index: 16 scientists 150–151 D-Index: 14 scientists 152–153 D-Index: 10 scientists 154–155 D-Index: 13 scientists 156–157 D-Index: 10 scientists 158–159 D-Index: 7 scientists 160–161 D-Index: 9 scientists 162–163 D-Index: 13 scientists 164–165 D-Index: 4 scientists 166 D-Index: 4 scientists 167+ D-Index: 98 scientists
40 D-Index 167+

This scientist: 63 D-Index — 49th percentile

49% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 167 D-Index or more.

Overview

Helen Rizos is affiliated with Macquarie University in Australia, focusing on research primarily within the fields of Biochemistry, Genetics and Molecular Biology, and Medicine. Their work spans several subfields, including Molecular Biology, Oncology, Immunology, Cancer Research, and Ophthalmology.

The scientist's research topics cover a range of areas related to cancer and immunotherapy. Key topics include:

  • Cancer Immunotherapy and Biomarkers
  • Immunotherapy and Immune Responses
  • Cancer Genomics and Diagnostics
  • Melanoma and MAPK Pathways
  • CAR-T Cell Therapy Research
  • Cutaneous Melanoma Detection and Management
  • Protein Degradation and Inhibitors

Helen Rizos has contributed to several publications in high-impact venues. Frequent publication venues include:

  • Journal of Clinical Oncology
  • Cancer Cell
  • Clinical Cancer Research
  • Annals of Oncology
  • Cancers

Selected recent papers provide insight into the focus of their research:

  • Transcriptional downregulation of MHC class I and melanoma de-differentiation in resistance to PD-1 inhibition, 2020, Nature Communications
  • Charge Conversional Biomimetic Nanocomplexes as a Multifunctional Platform for Boosting Orthotopic Glioblastoma RNAi Therapy, 2020, Nano Letters
  • Multiomic profiling of checkpoint inhibitor-treated melanoma: Identifying predictors of response and resistance, and markers of biological discordance, 2021, Cancer Cell
  • Evolutionary predictability of genetic versus nongenetic resistance to anticancer drugs in melanoma, 2021, Cancer Cell
  • Whole genome landscapes of uveal melanoma show an ultraviolet radiation signature in iris tumours, 2020, Nature Communications

Frequent co-authors collaborating on these works include:

  • Georgina V. Long
  • Richard A. Scolyer
  • Alexander M. Menzies
  • Jenny Lee
  • Matteo S. Carlino

Helen Rizos's research integrates molecular and clinical approaches to studying melanoma and other cancers, with an emphasis on mechanisms of resistance to therapies, immunological biomarkers, and genetic profiling. Their contributions extend across multiple study areas essential to advancing understanding of cancer biology and treatment responses.

Best Publications

  • Distinct Immune Cell Populations Define Response to Anti-PD-1 Monotherapy and Anti-PD-1/Anti-CTLA-4 Combined Therapy

    Tuba N. Gide;Camelia Quek;Alexander M. Menzies;Annie T. Tasker

  • BRAF inhibitor resistance mechanisms in metastatic melanoma; spectrum and clinical impact.

    Helen Rizos;Alexander M. Menzies;Gulietta M. Pupo;Matteo S. Carlino

  • Increased MAPK reactivation in early resistance to dabrafenib/trametinib combination therapy of BRAF-mutant metastatic melanoma

    Georgina V. Long;Carina Fung;Alexander M. Menzies;Gulietta M. Pupo

  • Circulating tumor DNA to monitor treatment response and detect acquired resistance in patients with metastatic melanoma.

    Elin S. Gray;Helen Rizos;Anna L. Reid;Suzanah C. Boyd

  • Acquired BRAF inhibitor resistance: A multicenter meta-analysis of the spectrum and frequencies, clinical behaviour, and phenotypic associations of resistance mechanisms.

    Douglas B. Johnson;Alexander M. Menzies;Lisa Zimmer;Zeynep Eroglu

  • Circulating Cytokines Predict Immune-Related Toxicity in Melanoma Patients Receiving Anti-PD-1-Based Immunotherapy.

    Su Yin Lim;Su Yin Lim;Jenny H. Lee;Jenny H. Lee;Tuba Nur Gide;Alexander M. Menzies;Alexander M. Menzies

  • Circulating tumour DNA predicts response to anti-PD1 antibodies in metastatic melanoma.

    J.H. Lee;J.H. Lee;J.H. Lee;G.V. Long;S. Boyd;S. Lo

  • Response of BRAF-Mutant Melanoma to BRAF Inhibition Is Mediated by a Network of Transcriptional Regulators of Glycolysis

    Tiffany J. Parmenter;Margarete Kleinschmidt;Kathryn M. Kinross;Simon T. Bond

  • Association Between Circulating Tumor DNA and Pseudoprogression in Patients With Metastatic Melanoma Treated With Anti-Programmed Cell Death 1 Antibodies.

    Jenny H. Lee;Jenny H. Lee;Georgina V. Long;Georgina V. Long;Alexander M. Menzies;Alexander M. Menzies;Serigne Lo

  • Transcriptional downregulation of MHC class I and melanoma de- differentiation in resistance to PD-1 inhibition.

    Jenny H. Lee;Elena Shklovskaya;Su Yin Lim;Matteo S. Carlino

  • Inducible but not constitutive expression of PD-L1 in human melanoma cells is dependent on activation of NF-κB.

    Kavitha Gowrishankar;Dilini Gunatilake;Stuart J. Gallagher;Jessamy Tiffen

  • Neoadjuvant systemic therapy in melanoma: recommendations of the International Neoadjuvant Melanoma Consortium

    Rodabe N. Amaria;Alexander M. Menzies;Alexander M. Menzies;Alexander M. Menzies;Elizabeth M. Burton;Richard A. Scolyer;Richard A. Scolyer

  • A melanoma-associated germline mutation in exon 1β inactivates p14ARF

    Helen Rizos;Susana Puig;Cèlia Badenas;Josep Malvehy

  • Resistance to combination BRAF and MEK inhibition in metastatic melanoma: Where to next?

    Sarah J. Welsh;Helen Rizos;Richard A. Scolyer;Georgina V. Long

  • WNT5A enhances resistance of melanoma cells to targeted BRAF inhibitors

    Jamie N. Anastas;Rima M. Kulikauskas;Tigist Tamir;Helen Rizos

  • Inhibition of mTORC1/2 Overcomes Resistance to MAPK Pathway Inhibitors Mediated by PGC1α and Oxidative Phosphorylation in Melanoma

    Y. N.Vashisht Gopal;Helen Rizos;Guo Chen;Wanleng Deng

  • Cancer Surveillance in Gorlin Syndrome and Rhabdoid Tumor Predisposition Syndrome.

    William D. Foulkes;Junne Kamihara;D. Gareth R. Evans;Laurence Brugières

  • Neoadjuvant dabrafenib combined with trametinib for resectable, stage IIIB-C, BRAFV600 mutation-positive melanoma (NeoCombi): a single-arm, open-label, single-centre, phase 2 trial.

    Georgina V Long;Georgina V Long;Robyn P M Saw;Robyn P M Saw;Serigne Lo;Omgo E Nieweg;Omgo E Nieweg

  • Mutations in the INK4a/ARF Melanoma Susceptibility Locus Functionally Impair p14ARF

    Helen Rizos;Artur P. Darmanian;Elizabeth A. Holland;Graham J. Mann

  • Differentiation of cucumber mosaic virus isolates using the polymerase chain reaction.

    Helen Rizos;Linda V. Gunn;Ray D. Pares;Michael R. Gillings

Frequent Co-Authors

Richard F. Kefford
Richard F. Kefford Macquarie University
Richard A. Scolyer
Richard A. Scolyer Royal Prince Alfred Hospital
Georgina V. Long
Georgina V. Long University of Sydney
Alexander M. Menzies
Alexander M. Menzies University of Sydney
Matteo S. Carlino
Matteo S. Carlino University of Sydney
John F. Thompson
John F. Thompson University of Sydney
Graham J. Mann
Graham J. Mann Australian National University
James S. Wilmott
James S. Wilmott University of Sydney
Peter Hersey
Peter Hersey University of Sydney
Grant A. McArthur
Grant A. McArthur Peter MacCallum Cancer Centre

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Expanding your expertise beyond Biology and Biochemistry can open doors to diverse careers in healthcare and science. Many students explore related online degrees to increase employment prospects and skillsets. For example, Health Information Management is a growing field, and students can find affordable online HIM programs to build a career focused on medical data, records, and compliance.

If you’re interested in working alongside clinicians but not directly with patients, consider the administrative path. Find out is medical billing and coding in demand to learn more about stability and growth in medical office roles.

Students passionate about nutrition science can pursue a specialty with a nutrition masters online, preparing for roles in dietetics, research, or wellness consulting.

Those drawn to technology and patient care may be interested in diagnostic imaging. Accredited sonography programs online provide pathways to become an ultrasound technician — a highly respected allied health profession.

Exploring these related online programs can help you craft a unique educational journey and pursue the healthcare career that best matches your strengths and goals.

Best Scientists Citing Helen Rizos

Trending Scientists

Recently Published Articles